Navicare Biotech Co., Ltd. AI Stock Analysis
Navicare Biotech Co., Ltd. (8472) AI Stock Analysis
Navicare Biotech Co., Ltd.
(TPEx:8472)
Navicare Biotech scores near the low end of the range. The dominant factor is a fragile financial profile: four straight years of losses, a severe gross margin decline from 62.9% to 36.0%, negative free cash flow, and a capital structure where debt (NT$327 million) now exceeds shrinking equity (NT$270 million). These risks outweigh the genuine progress seen in 42% revenue growth, a roughly 70% reduction in net loss, and near-breakeven operating cash flow. Technicals reinforce the caution, with the price far below all key moving averages and a deeply negative MACD signalling a persistent downtrend. Valuation provides no offset given negative earnings and no dividend. The investment case depends on management converting higher sales into positive margins and cash flow before leverage becomes a binding constraint.
Navicare Biotech Co., Ltd. (8472) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 870.83M
- Dividend Yield
- ―
- Average Volume (3M)
- 22.68K
- Price to Earnings (P/E)
- -70.1
- Beta (1Y)
- 0.38
- Revenue Growth
- 19.68%
- EPS Growth
- 71.10%
- Country
- TW
- Employees
- 80
- Sector
- General
- Sector Strength
- 55
- Industry
- Specialty Retail
Navicare Biotech Co., Ltd. Business Overview & Revenue Model
Company Description
Navicare Biotech Co., Ltd. is a Taiwanese enterprise that specializes in offering digital commerce and marketing solutions. The company operates a comprehensive online platform designed to showcase information for a diverse range of vendors. This dig...
Navicare Biotech Co., Ltd. Financial Statement Overview
Summary
Financials remain weak despite visible improvement. Revenue grew about 42% to roughly NT$478 million and net loss narrowed sharply to NT$23.3 million from NT$78.5 million, with operating cash burn nearly eliminated (-NT$3.2 million vs -NT$63.5 million). However, gross margin collapsed to 36.0% from 62.9%, the company has posted losses for four consecutive years, free cash flow is still negative, and the balance sheet has deteriorated materially — equity halved since 2020 to NT$270 million while debt rose from NT$14 million to NT$327 million, pushing debt-to-equity to 1.21. The turnaround is underway but the profile remains fragile.
Income Statement
33NegativeBalance Sheet
37NegativeCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 505.82M | 478.07M | 337.03M | 388.50M | 331.55M | 305.28M |
| Gross Profit | 181.10M | 172.16M | 211.87M | 281.82M | 280.10M | 283.92M |
| EBITDA | -4.42M | -15.09M | -54.05M | -46.75M | -81.95M | 22.46M |
| Net Income | -11.41M | -23.27M | -78.46M | -51.83M | -82.68M | 10.77M |
Balance Sheet | ||||||
| Total Assets | 994.20M | 1.05B | 999.54M | 1.18B | 1.21B | 1.05B |
| Cash, Cash Equivalents and Short-Term Investments | 165.13M | 230.31M | 99.12M | 141.01M | 242.88M | 658.58M |
| Total Debt | 318.39M | 327.47M | 260.97M | 248.84M | 232.22M | 13.26M |
| Total Liabilities | 735.35M | 779.12M | 714.47M | 818.89M | 796.38M | 521.48M |
| Stockholders Equity | 258.85M | 270.50M | 285.07M | 363.53M | 415.36M | 527.27M |
Cash Flow | ||||||
| Free Cash Flow | -25.28M | -4.12M | -72.22M | -145.37M | -474.62M | -74.47M |
| Operating Cash Flow | -24.43M | -3.17M | -63.49M | -108.19M | -68.41M | -68.70M |
| Investing Cash Flow | -80.43M | 8.65M | 49.10M | 68.92M | -157.56M | 70.60M |
| Financing Cash Flow | -24.44M | 74.59M | 7.07M | 10.17M | 205.06M | -49.52M |
Navicare Biotech Co., Ltd. Peers Comparison
Overall Rating
TW:417140Underperform- TW:847237.4Underperform
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:8472 | Navicare Biotech Co., Ltd. | 52.90 | -22.60 | -29.93% | |
| TW:4171 | GeneReach Biotechnology Corp. | 15.50 | -5.50 | -26.19% | |
| TW:6539 | DV Biomed Co., Ltd. | 36.20 | -17.63 | -32.76% | |
| TW:6850 | Bioptic Inc. | 27.65 | -12.75 | -31.55% | |
| TW:6879 | Tci Gene Inc. | 35.50 | -3.65 | -9.32% | |
| TW:7725 | LabTurbo Biotech Corporation | 21.00 | -1.81 | -7.93% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026